New drug cocktail aims to tame deadly transplant complication

NCT ID NCT07249346

Recruiting now Disease control Sponsor: Hannah Choe, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the drug ruxolitinib to standard medications (cyclophosphamide and tacrolimus) can prevent severe graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia. About 124 adults will receive the drug combination after transplant. The main goal is to see if this approach improves survival without severe GVHD at 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib, Cyclophosphamide, Tacrolimus
What this could lead to: If successful, this could lead to a safer, more effective way to prevent severe graft-versus-host disease after stem cell transplants, improving survival and quality of life.
What could go wrong: This is an early phase 2 trial with only 124 people, so results may not apply to everyone. The drug combination may still cause serious side effects or fail to prevent GVHD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia chronic myelomonocytic leukemia leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOMONOCYTIC LEUKEMIA LEUKEMIA MYELODYSPLASIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.